Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Squamous Cell Cancer Of The Head And Neck
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx. 2) Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration. 3) Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink).
You may not be eligible for this study if the following are true:
-
1) Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days [3 years]. 2) Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. 3) Patients with simultaneous primaries or bilateral tumors are excluded.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.